CoChat

Drug treatment for mood disorders in pregnancy

Gentile, Salvatore · 2011 · Current Opinion in Psychiatry

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

PURPOSE OF REVIEW: During the last few years, several researches, often showing contradictory findings, have investigated the safety of psychotropic medications used for treating mood disorders in pregnancy. Hence, the necessity exists to update this information constantly in order to ensure the safest option for the mother-infant pair. RECENT FINDINGS: The risk of fetal anomalies associated with early in-utero exposure to antidepressants seems to be increased after paroxetine and clorimipramine exposure, whereas prenatal exposure to nearly all antidepressants is linked to the potential onset of the Prenatal Antidepressant Exposure Syndrome. As regards classic mood stabilizers, the teratogenic risk historically reported with lithium should probably be softened, whereas valproate is the medication which shows the strongest association with fetal anomalies. An increased risk of autism-spectrum disorders and infant neurodevelopmental delay is also associated with valproate exposure through the placenta. No significant reproductive safety data are available on atypical antipsychotics, although such medications may indirectly increase the rate of fetal malformation by inducing gestational diabetes. SUMMARY: Avoiding the use of clorimipramine, paroxetine, valproate, and atypical antipsychotics during pregnancy is advisable. However, when starting or continuing pharmacological treatment during pregnancy, clinicians should consider not only the intrinsic iatrogenic risk of birth defects or perinatal complications, but also the general safety profile for the expectant mother. Indeed, specific adverse reactions (such as nausea, vomiting, constipation, and excessive weight gain) may aggravate the classic clinical findings of pregnancy, thus indirectly facilitating the occurrence of pregnancy complications and fetal and neonatal problems.

Overview

Integrity signals

Registry

Crossref · 10.1097/yco.0b013e3283413451

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 60 references

Cited by

See all 60

Metadata

Authors
Gentile, S.
Affiliations
Azienda Sanitaria Locale Salerno (IT)
Corresponding author
Gentile, Salvatore
Venue
Current Opinion in Psychiatry
Published
2011-01
Volume
24
Issue
1
Pages
34-40
ISSN
0951-7367 (ISSN-L)
OpenAlex
W2019932824
Cited by
60
References
60
Citations by year
2024: 4 · 2023: 2 · 2021: 1 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 2 · 2016: 1 · 2015: 6 · 2014: 12 · 2013: 8 · 2012: 7
FWCI
1.06
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
Keywords
mood disorders in pregnancy, antidepressants, paroxetine, clomipramine, valproic acid, lithium, atypical antipsychotics, fetal malformations, autism spectrum disorder, neurodevelopmental delay, gestational diabetes mellitus, teratogenicity, perinatal complications
MeSH terms
Abnormalities, Drug-Induced, Female, Humans, Infant, Newborn, Pregnancy, Prenatal Care, Prenatal Exposure Delayed Effects, Psychotropic Drugs, Risk Assessment, Perinatal Care, Mood Disorders, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug treatment for mood disorders in pregnancy. https://app.cochat.ai/papers/10.1097/yco.0b013e3283413451
The paper
Gentile, S. (2011). Drug treatment for mood disorders in pregnancy. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0b013e3283413451

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.